NPS Pharmaceuticals Inc

NPS Pharmaceuticals — Merger or Acquisition (March 2003)

11 slides from NPS Pharmaceuticals's merger presentation, Mar 18, 2003

  1. Slide 1: Science, Pipeline, Products: Creating a Biotechnology Leader

    Science, Pipeline, Products: Creating a Biotechnology Leader

  2. Slide 2: To Build a Sustainable Top-Tier Biotech Based On:

    To Build a Sustainable Top-Tier Biotech Based On: • A deep, diversified and sustainable pipeline • A clearly defined pathway to profitability • A fully integrated infrastructure and stable financial position

  3. Slide 3: Platform Technologies and Commercialization

    Platform Commercialization Technologies Preclinical Phase I Phase II Phase Ill & Manufacturing * PEGylation * SCA Projects + Single-Chain + PEG- Cytoxics Antibodies + PEGANTRON + Inhaled Leuprolide + ABELCET * ADAGEN + ONCASPAR. + DEPOCYT NPS mm ENZON

  4. Slide 4: The New Entity

    The New Entity

  5. Slide 5: Pipeline, Products & Technologies

    Pipeline, Products & Technologies

  6. Slide 6: ABELCET, ONCASPAR, DEPOCYT, ADAGEN

    • ABELCET ® • ONCASPAR ® • DEPOCYT ® • ADAGEN ®

  7. Slide 7: PREOS (Cinacalcet HCl)

    PREOS TM Cinacalcet HCI

  8. Slide 8: Market opportunity (U.S.)

    • Market opportunity (U.S.) — Primary HPT 500,000 patients — Secondary HPT 280,000 dialysis patients — Secondary HPT 800,000 predialysis patients

  9. Slide 9: Operational Overview

    Operational Overview

  10. Slide 10: Locations

    Locations Manufacturing: Indianapolis, IN Research: /Toronto, Canada _ Manufacturing: Toronto, Canada Research: Piscataway, NJ Manufacturing: South Plainfield, NJ Headquarters: Research: Bridgewater, NU Salt Lake City, Utah

  11. Slide 11: Science, Pipeline, Products: Creating a Biotechnology Leader

    Science, Pipeline, Products: Creating a Biotechnology Leader

NPS Pharmaceuticals — Merger or Acquisition (March 2003) on 6ix